 |
|
NewYorkBIO News
March 2017
|
|
NewYorkBIO thanks our Sustaining Members
|
|
Notes from Nathan
New York State is cultivating several developments that have the potential to affect the health of our life sciences community, and NewYorkBIO is engaged in shaping these movements so that our community members will be able to make the most of all of these opportunities while avoiding the hazards.
On the positive side of change, the New York life sciences community has been planning for the next developments from the Governor Cuomo and Mayor DeBlasio economic development initiatives.
NewYorkBIO surveyed our me
mbers and used the data to provide feedback and advice to legislators developing programs from the initiatives, helping to fine-tune the legislation and subsequent programs to meet the needs of our community.
Regrettably, some proposals in recent legislation do not offer such opportunities; rather, the price control measures being proposed in Albany represent a serious threat to innovation and development in New York life sciences. NewYorkBIO is working to educate legislators about the realities of these proposals as they move through the legislative process. On February 16th, I testified at the
Joint Legislative Public Hearing
about the harmful side effects of the price control proposals. But more importantly, we need to engage you, the membership of NewYorkBIO, in fighting for your interests in industry, academics, and innovation itself.
To this end, next week NewYorkBIO will host Advocacy Day, an opportunity for members and friends of NewYorkBIO to join voices and send a powerful message to our representatives in Albany. Together, we have the opportunity not only to educate legislators about the real-world repercussions about price controls, but we can also shape the outcomes of the economic development initiatives that are vital to the future of New York life sciences.
I look forward to seeing you at Advocacy Day and our March events.
|
|
|
Nathan Tinker
  
|
NewYorkBIO Welcomes Shanghai FDA
On February 22, 2017, NewYorkBIO hosted a briefing for the Shanghai Municipal FDA, introducing t
he delegation to the New York research landscape and discussing commercialization opportunities. Executive Director Nathan Tinker said, "NewYorkBIO is pleased to welcome Shanghai FDA to our offices here in New York for a wide-ranging discussion of economic development, approaches to marketing of therapies, and the New York research environment."
Members of the delegation, comprising 20 members of Shanghai Municipal FDA, enjoyed an extensive Q&A session with the executive director, including themes such as academic institutions and their relations to emerging industry, public/private partnerships, and direct-to-consumer marketing.
NewYorkBIO Executive Director Testifies in Albany
On February 16, 2017, NewYorkBIO Executive Director Nathan Tinker testified at the Joint Legislative Public Hearing in Albany to express opposition to Part D of the Health and Mental Hygiene Article
VII budget proposal, which would mandate price controls on biopharmaceutical products. NewYorkBIO opposes the proposal on the grounds that it would act as a disincentive to innovation for therapy makers who would offer their products in the New York market. Further, Tinker said to the Committee, "the proposal would stifle the development of innovative therapies that target some of the most challenging and debilitating diseases in our lifetime."
NewYorkBIO members have the opportunity to express their own thoughts on the proposal when they attend New York State Life Science Advocacy Day on March 6-7, 2017.
NewYorkBIO Hosts Rousing Reception at BIO CEO & Investor Conference 2017
On February 12th, NewYorkBIO served as host to a lively reception for over 200 attendees of the BIO CEO & Investor Conference. Guests, including investors, financiers, innovators, and scientists, enjoyed food and wine with a view of the Chrysler Building from the rooftop of the Kimberly Hotel.
NewYorkBIO was also Local Co-Host of BIO CEO & Investor, considered the preeminent investment conference on the East Coast; the annual NewYorkBIO reception launches the conference activities. A
s one attendee told NewYorkBIO News, "The NewYorkBIO reception is truly a lovely break from the intensity of the conference, and it helps me get the lay of the land from my fellow life scientists." Looking out at the Chrysler Building through the glassed ceiling, she added, "Besides, you can't beat the view."
BREAKING: Malcolm Gladwell to Kick-Off NewYorkBIO Annual Conference
NewYorkBIO announced that bestselling author and influential thinker Malcolm Gladwell is slated to deliver the Opening Keynote Address at this year's Annual Conference on Wednesday, May 10, 2017, at 9:
00am. NewYorkBIO's Nathan Tinker said, "We are thrilled to offer our conference-goers this opportunity to hear from one of the great business thinkers of our time."
The 2017 Annual Conference, "New York Life Science at a Tipping Point," featuring talks, panels, partnering sessions, networking opportunities, vendors, and much more, will be held on May 10-11 at 10 on the Park @ Time Warner Center.
|
 New York Legislative Update
NEW YORK CITY AND STATE
The budget provisions announced in December and January, including b
oth the state and city life science economic development initiatives, are moving through the legislative process. NewYorkBIO is actively engaging with both the City and the State to advocate for our membership's
concerns.
Governor Cuomo's $650 million state-wide life science economic development program
focuses on development and investment in commercial life science across New York State.
NewYorkBIO welcomes important provisions of the governor's initiative:
- Addressing the lack of affordable lab space, including designating tax-free zones under the StartUP NY program as well as funding for the creation of new life science incubators in the state. NewYorkBIO also supports a restructuring of the StartUP NY program make it easier for companies to find tax-free space and to aid in the development of life science clusters tied to institutions of higher learning.
-
Increasing access to capital for early and growth-stage companies, including a refundable corporate tax credit to help early stage companies access capital. NewYorkBIO applauds this position and encourages the state to revisit the refund ability of other existing tax credits for early and growth stage companies.
- Attracting and retaining top scientific talent, including the implementation of a life sciences researcher recruitment program. NewYorkBIO remains committed to creating opportunities to increase the connectivity of our industry.
NYC Mayor Bill de Blasio's proposal aims to deliver a total investment of more than $500 Million to New York City's life science sector over the next 10-25 years with the goal of creating 16,000 jobs for New Yorkers.
NewYorkBIO applauds the Mayor's
program to strengthen the life sciences ecosystem in NYC through strategic initiatives and public-private partnerships in key areas:
- Spurring the creation of additional commercial lab space in New York, with targeted tax incentives as well as direct investment to fund incubators and innovation centers. NewYorkBIO strongly feels that these provisions will help offset the high cost of built-out lab space, while at the same time encouraging co-location among companies and among companies with academic partners.
- Developing a pipeline for academic talent, both by attracting talent to New York and by cultivating it through our world class academic institutions. Employ New Yorkers
- Building a Life Sciences Management Corps and the Mayor's Life Sciences Advisory Council. NewYorkBio encourages the groups to investigate how smaller companies may begin to pool some shared services to compete effectively for talent.
NewYorkBIO has been advocating for this kind of large-scale thinking and investment, and we applaud the vision put forth by both
Governor Cuomo and Mayor de Blasio to grow this vital industry.
Nathan Tinker, NewYorkBIO Executive Director said of the initiatives, "New York is truly poised to build the world's foremost life science cluster, with a range of business, research, and patient assets unavailable anywhere else. NewYorkBIO has a wide array of experts within our membership who are enthusiastic about these opportunities to strengthen our industry while helping the next generation of innovators to succeed. We look forward to to working with the governor, the mayor, and their administrations to make New York the premiere destination for life sciences innovation and research."
For more information:
NEW YORK STATE
NewYorkBIO Opposes Effort to Mandate Price Controls on Biopharmaceutical Products
NewYorkBIO strongly opposes Part D of the Health and Mental Hygiene Article VII budget proposal. This
proposal would allow the state to impose draconian price controls on all pharmaceuticals sold in New York and
thereby disincentivize innovative drug makers from offering their products in the New York market. Most
importantly, it would stifle the development of innovative therapies that target some of the most challenging and
debilitating diseases in our lifetime.
NewYorkBIO To Host New York Bioscience Advocacy Day
Once a year, NewYorkBIO hosts Bioscience Advocacy Day, inviting life science and health executives from across New York to come to Albany for a day of legislative briefings and advocacy.
For 2017, NewYorkBIO will host delegations in one-on-one and small group meetings with legislators, agencies, and departments on
March 6-7, 2017.
We look forward to another great day of engaging with Members of the State Legislature and their senior staff on the most important legislative issues facing the biotechnology industry in New York, including fair pricing, economic development, and patient access to innovative therapies.
NewYorkBIO will schedule all legislative meetings and provide attendees with a legislative briefing prior to their visits to the Statehouse. Attendees meet in small groups with legislators, agencies, key offices and committees, and senior staff. Each group will be accompanied by a NewYorkBIO staff representative for all visits.
Because these issues are so important to the bioscience community, there is no registration fee for members or non-members to attend Bioscience Advocacy Day.
It is always our goal to make the Bioscience Advocacy Day as easy as possible for our visiting attendees; please do not hesitate to contact us with questions.
FEDERAL UPDATE
NewYorkBIO will Lead Delegation To BIO Legislative Fly-In, Washington DC
On April 4 and 5, 2017, NewYorkBIO will lead the New York delegation for t
he BIO Legislative Day Fly-In. The Fly-In is a free event hosted by BIO as a benefit of membership. Attendees are invited to participate in a legislative briefing and networking reception on Tuesday, April 4. On Wednesday April 5 attendees will visit congressional offices and participate in meetings with New York senators, representatives, and staff. Likely topics for discussion include ACA reform, FDA reform, the regulatory landscape, and patent reform.
|
Upcoming Events
2017 New York Bioscience Advocacy Day and Legislative Fly-in
Wednesday, May 10, 2017
2017 NewYorkBIO Annual Conference
|
Richard P. Lifton
President, The Rockefeller University
Thursday, April 20
7:30AM
Sponsored by
|
|
Welcome New Members
2X Oncology
New York, NY
Advanced Accelerator Applications USA, Inc.
Milburn, NJ
Axitech, LLC
Holtsville, NY
Bioconnex
Albany, NY
BioHealthWays, Inc.
Brooklyn, NY
BioWorks Inc.
Victor, NY
Center For Aquatic Animal Research and Management
Wingdale, NY
Clarapath
New York, NY
ConquerAb Inc.
Philadelphia, PA
Coté Orphan, LLC
Silver Spring, MD
DrinkSavvy Inc.
Brooklyn, NY
FitBiomics
Boston, MA
Halloran Consulting Group, Inc.
Boston, MA
Kinnos
Brooklyn, NY
Klus Pharma Inc. Biologics
Cranbury, NJ
|
Longfellow Real Estate Partners, LLC
Boston, MA
Lucerna, Inc.
Brooklyn, NY
Matritek, Inc.
New York, NY
Mosaica Therapeutics Inc.
Howard Beach, NY
Moses & Singer LLP
New York, NY
NangioTx
New York, NY
Nevakar, LLC
Bridgewater, NJ
Raadysan Biotech Inc.
Fishkill, NY
Sanofi
Bridgewater, NJ
SUNY Albany
Albany, NY
Taithera, Inc.
New York , NY
Tri-Medix LLC
Larchmont, NY
TRUETOX Laboratories
Garden City, NY
WRS Therapeutics
New York, NY
|
|
|
|
NewYorkBIO Member News
If you have news to share with our 20,000+ subscribers, please send notes or releases to
AbbVie Inc.
AbbVie announced that the U.S. Food and Drug Administration
(FDA) has accepted its New Drug Application (NDA) and granted priority review for its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), being evaluated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C virus.
Acorda Therapeutics, Inc.
Acorda announced that Catheryine D. Strader, PhD, has joined Acorda's Board of Directors.
Actinium Pharmaceuticals, Inc.
Advanced Accelerator Applications USA, Inc.
Advanced Accelerator Applications USA announced that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating 177Lutetium Dotatate, an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors.
Advaxis, Inc.
Advaxis, Inc. and
SELLAS Life Sciences Group announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent using Advaxis' proprietary Lm-based antigen delivery technology with SELLAS' patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S).
Albany College of Pharmacy and Health Sciences
Assistant Professor Tim LaRocca and
Associate Professor Meenakshi Malik have each been awarded a three-year research grant totaling $480,000 by the National Institutes of Health
.
Alexandria Center/Alexandria Real Estate
The Alexandria Center for Life Science
announced that
Alexandria LaunchLabs®
has selected a leading-edge group of life science startups as its first member companies.
Read More
Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc., announced a significant expansion of its U.S. and Global patent portfolio
Argon Medical Devices Biocoatings Corp.
Argon Medical Devices, Inc., announced
that it has completed the sale of its Critical Care business to Merit Medical Systems, Inc.
Associated Medical Schools of New York
The Associated Medical Schools of New York is urging the New York State Legislature to dedicate $50 million of the $650 million allocated to the life sciences sector in the 2017-2018 Executive Budget to the state's 16 medical schools.
Astellas Pharma US
BioWorks' OMRI Listed biofungicide has been approved for use in Canada on certain plants.
Bristol Myers Squibb
BMS
announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Read More
Cellectis, Inc
Cellectis, Inc., announced that four new members joined Cellectis' Clinical Advisory Board.
Celgene Corporation
Celgene announced that the European Commission has approved REVLIMID® (lenalidomide) as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation
Read More
Cellectis, Inc.
Cellectis, Inc., has received an Investigational New Drug approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1 clinical trials with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first allogeneic, "off-the-shelf" gene-edited CAR T-cell product candidate that the FDA has approved for clinical trials.
Read More
Celmatix, Inc.
Celmatix was featured in the Fast Company article: "Why Celmatix is One of the Most Innovative Companies of 2017."
Read More
City University of New York
Cold Spring Harbor Laboratory
Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered that a protein called Importin-11 protects the anti-cancer protein PTEN from destruction by transporting it into the cell nucleus.
Columbia University Medical Center
Bristol-Myers Squibb Company announced that Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac) have joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance Immuno-Oncology (I-O) science and translational medicine to improve patient outcomes.
ConSynance Therapeutics, Inc
.
ConSynance Therapeutics announced that it is exploring small leptin mimetics for the treatment of Alzheimer's Disease.
Read More
Eli Lilly and Company
Eli Lilly and Company
and Incyte Corporation announced that additional detailed results from RA-BEAM - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - were published in the New England Journal of Medicine.
Gilda's Club's Clubhouse received a makeover from the Changing Images Art Foundation.
HHMI/The Rockefeller University
The Associated Press and HHMI's Department of Science Education announced a yearlong collaboration on two pilot projects designed to expand AP's science journalism.
iCell Gene Therapeutics
iCell Gene Therapeutics
announced the publication of preclinical CD5CAR NK cell data in Leukemia
Immix Biopharma
Immix Biopharma, Inc. is announcing its compassionate use policy.
International AIDS Vaccine Initiative (IAVI)
The International AIDS Vaccine Initiative (IAVI) announces an expanded partnership with Oxford University to develop a broadly effective AIDS vaccine candidate.
Johnson & Johnson (NewYorkBIO Sustaining Member)
Johnson & Johnson
announced it has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott
Kinnos
Kinnos announced the closing of $1 million in seed round funding.
Lodo Therapeutics Corporation
Accelerator Corporation launches Lodo Theraepeutics with $17 million series a to develop therapies derived from natural products.
Merck & Co Inc.
Merck Inc. announced that the FDA has accepted for review the supplemental
Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company's anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer
New York Medical College
Congresswoman Nita M. Lowey announced a $71,137 National Institute on Aging (NIA) grant to New York Medical College to study DNA repair in ovarian aging.
Read More
Pfizer Inc.
Pfizer Inc. announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA)
Roche
Roche, Inc., announced that the
European Commission has granted a conditional marketing authorisation for Alecensa® (alectinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Royalty Pharma Management LLC
Royalty Pharma announced $100 million acquisition of royalty rights in cardiovascular drug Omecamtiv Mecarbil from Cytokinetics.
Sanofi
Sanofi and
Lonza announced that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland
SUNY Downstate Medical Center
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the
Journal of Neurotrauma.
Read More
Syndax Pharmaceuticals, Inc.
Syntax Pharmaceuticals, Inc., announced that Richard P. Shea is stepping down from his position on the Syndax Board of Directors and is joining the Company as Chief Financial Officer
Taconic Biosciences, Inc.
Tactic Biosciences announced the launch of the
EZcohort™ program, providing researchers faster and easier access to unique mouse models.
Weill Cornell Graduate School of Medical Sciences
Dr. Iliyan Iliev, an assistant professor of immunology in medicine at Weill Cornell Medicine, has been awarded a one-year, $100,000 grant from the
Kenneth Rainin Foundation to study the behavior of fungi in the immune system when patients with inflammatory bowel disease are administered a form of immunotherapy.
|
|
NewYorkBIO membership has its privileges:
EMPLOYERS: Find Your Next Great Hire
- EMAIL your job to qualified professionals
- PLACE your job in front of our highly qualified members
- SEARCH our resume database of qualified candidates
- MANAGE jobs and applicant activity right on our site
- LIMIT applicants only to those who are qualified
- FILL your jobs more quickly with great talent
PROFESSIONALS: Keep Your Career on the Move
- POST a resume or anonymous career profile that leads employers to you
- SEARCH and apply to hundreds of fresh home health care jobs on the spot by using robust filters
- SET UP efficient job alerts to deliver the latest jobs right to your in-box
- ASK the experts about your career issues
|
|
|
|
|
|
